Last updated on November 2019

TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

Brief description of study

This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.

Clinical Study Identifier: NCT03856099

Find a site near you

Start Over

Austin Hospital

Heidelberg, Australia
  Connect »